Yoshiharu Horie

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator‐controlled, double‐blind study

Ryuzo Kawamori, Nobuya Inagaki, Eiichi Araki et al. · Diabetes Obesity and Metabolism · 2011 · 112 citations

Medicine, Pharmacology, Pharmacotherapy +15

Mitochondrial alterations in dorsal root ganglion cells in sporadic amyotrophic lateral sclerosis

Shoichi Sasaki, Yoshiharu Horie, Makoto Iwata · Acta Neuropathologica · 2007 · 75 citations

Life Sciences, Neurology, Neuroscience +16

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects

Akiko Sarashina, Shogo Sesoko, Mitsuyoshi Nakashima et al. · Clinical Therapeutics · 2010 · 59 citations

Medicine, Endocrinology, Pharmacology +13

Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients

Yoshiharu Horie, Shigeto Kanada, Hirotaka Watada et al. · Clinical Therapeutics · 2011 · 45 citations

Medicine, Pharmacokinetics, Pharmacology +13

The Japanese Aggrenox (Extended-Release Dipyridamole plus Aspirin) Stroke Prevention versus Aspirin Programme (JASAP) Study: A Randomized, Double-Blind, Controlled Trial

Shinichiro Uchiyama, Yasuo Ikeda, Yasuhisa Urano et al. · Cerebrovascular Diseases · 2011 · 42 citations

Pharmacy, Pharmacology, Pharmacotherapy +17